Physician profile
Jun Li
NPI 1467955336
$3,675.67
in general payments reported to CMS, 2019-2025
18 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $433 · 2024: $1,774 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.38 |
| Education | $304.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $773.71 | 2023-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $521.44 | 2023-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $455.32 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $405.92 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $263.49 | 2023-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $209.81 | 2024-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $203.39 | 2024-2025 | Jynarque |
| Glaxosmithkline, LLC. | $173.00 | 2024-2025 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $123.35 | 2023-2025 | Tarpeyo |
| Amgen INC. | $111.60 | 2024-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.84 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $71.26 | 2024 | |
| Esperion Therapeutics, INC. | $55.68 | 2023-2025 | Nexletol |
| Vifor Pharma, INC. | $53.28 | 2025 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.05 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.33 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $40.95 | 2025 | Gemtesa |
| Shield Therapeutics INC | $18.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.